Nov. 9, 2009 (Business Wire) — Vivakor, Inc. (OTCBB: VIVK) today announced it has completed a pilot product evaluation program with consumer product specialist, Regeneca International, Inc. (www.regeneca.com). The product evaluation involved Vivakor’s proprietary nutraceutical formulation derived from natural sources. Research has shown that phytochemicals, vitamins, minerals, and fiber, all present in fruits and vegetables, work synergistically to promote health and lower disease risk. For this reason, many organizations, such as the National Cancer Institute and The American Heart Association, recommend getting phytochemicals from whole foods, such as fruits and vegetables. The Vivakor product is a whole food supplement designed to deliver these essential nutrients to the users in small, single dose units.

Regeneca’s President, Larry Walter gave his thoughts on the study. “Not only are the consumer study results impressive, but the overall opportunity to work with the team of professionals at Vivakor gives us a great deal

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Friday October 23, 2009

DrStockPick.com Stock Report!

**************************************************************

Powersafe Technology Corp.’s (Other OTC: PSFT.PK) Subsidiary Amplification Technologies has patented a revolutionary new solid-state semiconductor technology solution for low-level signal detection: multichannel Discrete Amplification (DA). The patented DA platform technology, invented by company scientists, is a breakthrough in the design of photon detectors, providing these detectors with unique competitive advantages. Use of DA in semiconductor detectors increases their sensitivity markedly, and enables the creation of new detector systems for various applications including medical diagnostics, security systems,

...

Last week, Keryx Biopharmaceuticals, Inc. (KERX) announced that its renal cancer drug KRX-0401 (perifosine) met both primary and secondary endpoints in a mid-stage trial. KRX-0401 is in-licensed by Keryx from Aeterna Zentaris Inc. (AEZS) in the US, Canada and Mexico. The data was presented at the eighth International Kidney Cancer Symposium in Chicago. The candidate demonstrated efficacy, safety and tolerability in metastatic renal cell carcinoma (RCC) patients whose disease progressed after failing treatment with both a VEGF (vascular endothelial growth factor) receptor inhibitor and an mTOR (mammalian target of rapamycin) inhibitor. Even though the drug was well-tolerated, the most common adverse events were gastrointestinal discomfort and fatigue. RCC is the most common of all kidney tumors, accounting for 85% of the cases. The advanced form of the disease is resistant to standard therapies such as radiation and chemotherapy. The initial treatment in most cases ...

Last week, Keryx Biopharmaceuticals, Inc. (KERX) announced that its renal cancer drug KRX-0401 (perifosine) met both primary and secondary endpoints in a mid-stage trial. KRX-0401 is in-licensed by Keryx from Aeterna Zentaris Inc. (AEZS) in the US, Canada and Mexico. The data was presented at the eighth International Kidney Cancer Symposium in Chicago. The candidate demonstrated efficacy, safety and tolerability in metastatic renal cell carcinoma (RCC) patients whose disease progressed after failing treatment with both a VEGF (vascular endothelial growth factor) receptor inhibitor and an mTOR (mammalian target of rapamycin) inhibitor. Even though the drug was well-tolerated, the most common adverse events were gastrointestinal discomfort and fatigue. RCC is the most common of all kidney tumors, accounting for 85% of the cases. The advanced form of the disease is resistant to standard therapies such as radiation and chemotherapy. The initial treatment in most cases ...

If there is one disease that has plagued our country and people across the globe, it would be cancer. Perhaps there is not a more tragic situation than when a child is stricken down with the deadly disease. One company is trying to make headway into Pediatric Cancer. That company is Hana Biosciences.

The San Francisco based Hana Biosciences is a biopharmaceutical company that has dedicated their resources and time to developing and commercializing new and differentiated cancer therapies with a plan to improve and enable standards of care amongst cancer patients. Hana took a major step towards achieving this goal with the announcement that they have entered into a Clinical Trial Agreement (CTA) with the Center for Cancer Research (CCR) at the National Cancer Institute for the co-development of Marquibo which is a vincristine sulfate liposomes injection in refractory pediatric cancer.

The CTA will occur over five-years

...

On Friday, Trubion Pharmaceuticals, Inc. (TRBN) agreed to jointly develop and commercialize TRU-016 globally with Facet Biotech Corp. (FACT).  TRU-016 is undergoing early-stage studies for chronic lymphocytic leukemia (CLL).   The deal requires Facet to make a $20 million upfront payment to Trubion coupled with an additional $176.5 million on the achievement of certain milestones. Further, Facet has agreed to buy 2.24 million shares of newly issued Trubion common stock for $10 million. The companies have agreed to contribute equally towards costs related to development, commercialization and promotional activities. All global operating profits will be shared equally.   The TRU-016 program is focused on the development of a novel CD37-targeted therapy for B-cell malignancies, such as Non-Hodgkin's lymphoma (NHL) and CLL. CD37 is a clinically validated target for the treatment of B-cell malignancies and TRU-016 has been designed for a desired therapeutic label surrounding B-cell depletion in these

...

Antigenics, Inc.

(Public, NASDAQ:AGEN) is a buy

About: Antigenics Inc. (Antigenics), is a biotechnology company focused on developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches.

News Headlines:

Antigenics, Inc. Gets FDA Approval For Orphan Drug Designation To Oncophage For Treatment Of Glioma

Antigenics, Inc. announced that Oncophage (vitespen) has been granted orphan drug status for the treatment of glioma (brain cancer) by the US Food and Drug Administration (FDA). FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma “Glioma is such an aggressive and challenging cancer that when patients are diagnosed with recurrence of this life threatening disease, they rarely live beyond six months,” said Andrew T. Parsa, MD, PhD, associate

...

MultiCell Technologies, Inc., an integrated biopharmaceutical company based in Rhode Island, announced today that it has entered into a cooperative research and development agreement with Maxim Biotech, Inc., a non-public Maryland-based medical research products company. The focus of the research will be the development of products for working with liver stem cells in the detection and treatment of liver cancer.

Although not one of the most common types of cancer in the U.S., liver cancer is still deadly. Nationwide there were over 21,000 new cases of primary liver cancer and intrahepatic bile duct cancer in 2008 according to the National Cancer Institute. Approximately 85% of those cases were fatal. Worldwide, liver cancer is more common due to the prevalence of hepatitis infection. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C, is the most common cancer in some parts of the world.

One of the problems in dealing with the disease

...

Medivisor Inc. is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. Headquartered in Huntington Station, New York, the Company exclusively serves the bioscience and pharmaceutical markets. They offer specialized medical marketing consulting, graphic design, web site marketing strategy, and market research.

Medivisor provides concise and timely medical information through the internet on advances in medicine and changes within the industry. They also utilize sales representatives who make periodic visits to healthcare providers. The Company’s business model provides a cost effective, efficient way to make medical personnel aware of opportunities, tools, information, and resources available to them as part of their patient care. Medivisor also collaborates with pharmaceutical distribution companies to market and grow sales of new and current drugs. This aids in lowering current marketing costs and helps to bring products and services to market.

Medivisor reached an exclusive marketing and distribution agreement with

...

The rise of individualized medicine is the new direction in oncology. More sophisticated and complex testing will be required to select the right therapy for the right patient at the right time in their treatment. Clarient has created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary “companion” diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient has over 1,700 targeted cancer therapeutics in their pipeline.

Todd S. Barry, M.D., Ph.D. has joined Clarient’s medical staff as Medical Director. Dr. Barry was the Director of Molecular Pathology & Hematopathology for six years at PhenoPath Laboratories, PLLC, a national reference laboratory located in Seattle. Prior to that, he did his Fellowship Training in Hematopathology at the National Cancer Institute. He has also published numerous professional studies and is

...